AdvanCell Closes A$18M Series B Funding Led by Morningside
14.9.2022 17:16:00 EEST | Business Wire | Press release
AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.
Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and delighted that we will continue our rapid growth with the support of our shareholders. We have had a long-term relationship with our lead investor, Morningside, and are excited to come closer still to our goal to 'Change the Course of Cancer Treatment.'”
Targeted Alpha Therapies represent the most exciting opportunity to treat currently untreatable cancers. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell. AdvanCell believes this precise and powerful treatment will rapidly become a leading pillar of cancer treatment, providing treatments for diseases for which there are currently no effective options. Targeted Alpha Therapies demonstrate incredible efficacy, however widespread adoption and large commercial product launches require a scalable and reliable global isotope supply. AdvanCell was established to solve this problem.
AdvanCell’s ability to produce isotope on-demand and at scale, and its in-house radiopharmaceutical manufacturing expertise positions AdvanCell to play a leading role in this rapidly growing market. With additional support from NSW Health Medical Devices Fund and the Federal government’s Research & Development Tax Incentive, AdvanCell has developed a world-first scalable manufacturing platform to produce alpha-emitting isotopes for research, pre-clinical and clinical use and to advance its own and its partners' radiopharmaceutical products.
Anthony Aiudi from Morningside commented, “AdvanCell is leveraging its ability to make alpha isotopes at scale and in clinically useful amounts along with its radiochemistry expertise, to develop an exciting portfolio of Targeted Alpha Therapies. Targeted Alpha Therapies hold incredible promise however their development has been hamstrung by a lack of radioisotope supply. Together with the team at AdvanCell, we look forward to writing a new chapter in oncology, to target large patient populations with significant unmet needs.”
Mr Aiudi has been appointed to the Board of AdvanCell, joining Mr Adamovich, Bill Ferris AC, co-founder of CPE Capital, Adrian “Adi” Patterson, former Australian Nuclear Science and Technology Organisation (ANSTO) CEO and Kevin Cameron, CEO of Ionetix.
Bill Ferris AC, Chair remarked, “Our executive team has articulated a credible pre-clinical and clinical pathway for the delivery of the Company’s novel Targeted Alpha Therapies. Having successfully developed the manufacturing platform essential for the reliable and scalable supply of isotopes, the Company is on schedule with its pre-clinical work and is now moving into first-in-human trials. AdvanCell is on track to become a leading radiopharmaceutical company with a platform technology enabling novel cancer treatments.”
About AdvanCell
AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. AdvanCell’s Targeted Alpha Therapies are powered by a platform technology – a world-first alpha isotope generator that addresses the greatest unmet need in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell has a world-class team and is honoured to be advised by an outstanding Board of Directors and Scientific Advisory Board. For more information visit www.advancell.com.au
About Morningside
Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. Morningside partners with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility. For more information visit www.morningside.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005846/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Brings Libra AI Workflows into InView Legal for Belgian Legal Professionals17.6.2026 10:00:00 EEST | Press release
Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in InView Legal (formerly known as Jura) in Belgium. This integration brings generative AI features directly into the research workflow of legal professionals and allows a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Belgium in February, combining AI with authoritative legal content from InView Legal and supporting lawyers across their full workflow, from research to analysis and document drafting. With the newly launched Libra add-in for InView Legal customers can use Libra’s AI functionalities for drafting, review and analysis in one unified environment, handling their work end-to-end. The solution reflects a broader market shift from standalone digital databases towards integrated, AI-powered workflows. “The integration of Libra into InView Legal marks the next step in the evolution of legal work: from
Zoya Technologies Launches Clinical AI Terminal Engineered to Operate Without Internet Connectivity17.6.2026 10:00:00 EEST | Press release
Almost every digital health system assumes the internet will be there. Zoya Technologies today launched the ZoyeMed 3.0 Resilience Edition, a clinical AI terminal engineered to deliver a complete medical episode without an internet connection at any stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617381037/en/ The ZoyeMed 3.0 Resilience Edition - a fully standalone clinical AI terminal engineered to operate without internet connectivity, integrating point-of-care diagnostics, examination tools, and on-device AI in a single 5-square-metre footprint (Photo: AETOSWire) Continuity of care is the first casualty of infrastructure disruption. Disasters, grid instability, and remote deployments routinely sever the connectivity that cloud-dependent systems require - when clinical capacity is most needed. The Resilience Edition is a fully standalone configuration of ZoyeMed 3.0. The complete Longitudinal Multimodal Model and
Owl Labs Launches Owl 360 Services, Bringing Enterprise Grade Intelligence to Hybrid Meetings17.6.2026 10:00:00 EEST | Press release
Owl Labs, the leader in 360-degree AI-powered video conferencing and hybrid collaboration technology, today announced Owl 360 Services, its first subscription service built to meet the needs of IT administrators. As organisations look to support hybrid work with deeper video enablement across more spaces, Owl 360 Services delivers three subscription tiers, offering dedicated support, centralised device management, proactive insights, and warranty coverage scaled to the size and complexity of the deployment. From launch, every Owl Labs device worldwide, whether newly purchased or already owned, is enrolled in the Core tier at no additional cost, giving all customers built-in analytics from the start. The Enhanced tier, available for direct purchase globally from this summer, adds advanced analytics, dashboards, meeting record history, and API integrations. A premium Enterprise tier, offered exclusively through authorised Owl Labs channel partners, is available now in North America, with
Cognite Launches Novel Integrated Supply Chain Offering to Deliver Unprecedented Business Value with AI17.6.2026 09:00:00 EEST | Press release
Cognite, a global leader in Industrial AI, today announced the launch of its Integrated Supply Chain offering. This new solution area extends the Cognite AI and Data Platform beyond the plant, equipping industrial teams with real-time visibility, insights, and cross-functional context to finally bridge the long-standing data gap between production and supply chain operations. Unifying these siloed teams empowers organizations to respond faster and smarter to internal or external disruptions, execute adaptive pivots, and better protect margins. The divide between production and supply chain operations has increased over time, as competing KPIs, organizational initiatives, and specialized software further fragment decision-making processes. As a result, any operational disruption can force costly, reactive firefighting; supply chain penalties; and production stalls, where slow decision making can cost up to 5% of top-line revenue or over $50M annually for a $1B organization[1]. “Right no
Tigo Energy Delivers New GO Optimized Energy Storage System to European Residential Market17.6.2026 07:00:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the GO Battery, as part of the GO Optimized ESS, is now shipping for European market customers, fulfilling the preorder commitments made when the product was introduced in April 2026. The Company will showcase live system demonstrations of the GO Optimized ESS at Intersolar Europe 2026, taking place June 23–25 at Messe München in Munich, Germany, at booth B3.140. Weiss-Blau GmbH, a member of the Tigo Installer Loyalty Program, will join Tigo at the show as one of the first installation companies to deploy the system in the European residential market. The GO Battery's modular architecture, built on 3.68kWh units configurable from 7.3kWh to 47.9kWh, is designed to give installers flexible sizing options for the full range of European residential applications, from compact apartments to larger homes with higher energy demands. Backward-compatible with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom